Literature DB >> 17955025

AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method.

Ronald L Klein1, Robert D Dayton, Jason B Tatom, Karen M Henderson, Phillip P Henning.   

Abstract

We compared adeno-associated virus (AAV) serotypes for expression levels of green fluorescent protein (GFP) in the adult rat hippocampus by biophotonic imaging. Preparations of AAV serotypes 8, 9, Rh10, and Rh43 incorporating cytomegalovirus (CMV) promoter-driven GFP were purified by a CsCl method. Neither AAV Rh10 nor AAV Rh43 produced greater levels of GFP than AAV8, which was used as a reference. For AAV9, there was an increase relative to AAV8. The CsCl-purified AAV8 displayed an astroglial transduction pattern in contrast to the expected neuronal expression of other AAVs. After preparing the same CMV-GFP plasmid in AAV8 with an iodixanol purification method, the expected neuronal pattern resulted. The astroglial expression with the CsCl AAV8 was probably due to relatively high levels of protein impurities. We compared the CMV promoter with the CMV/chicken beta-actin (CBA) promoter in the context of AAV8, both prepared by iodixanol, and found the CBA promoter to produce stronger GFP expression. At two doses of vectors optimized for serotype, promoter and purification, we did not observe serotype differences among AAV8, AAV9, or AAV Rh10. The purification method can therefore impact the transduction pattern as well as the results when comparing serotype strengths.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17955025      PMCID: PMC2987640          DOI: 10.1038/sj.mt.6300331

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  26 in total

Review 1.  A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis.

Authors:  Luis H Barbeito; Mariana Pehar; Patricia Cassina; Marcelo R Vargas; Hugo Peluffo; Liliana Viera; Alvaro G Estévez; Joseph S Beckman
Journal:  Brain Res Brain Res Rev       Date:  2004-12

2.  Recombinant adeno-associated virus serotype 2 effectively transduces primary rat brain astrocytes and microglia.

Authors:  Yan Gong; Shuzhen Chen; Christopher F Sonntag; Colin Sumners; Ronald L Klein; Michael A King; Jeffrey A Hughes; Edwin M Meyer
Journal:  Brain Res Brain Res Protoc       Date:  2004-11

Review 3.  Recombinant adeno-associated viral vectors in the nervous system.

Authors:  Corinna Burger; Kevin Nash; Ronald J Mandel
Journal:  Hum Gene Ther       Date:  2005-07       Impact factor: 5.695

Review 4.  New recombinant serotypes of AAV vectors.

Authors:  Guangping Gao; Luk H Vandenberghe; James M Wilson
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

5.  Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.

Authors:  M L D Broekman; L A Comer; B T Hyman; M Sena-Esteves
Journal:  Neuroscience       Date:  2006-01-18       Impact factor: 3.590

6.  Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat.

Authors:  Sharon Reimsnider; Fredric P Manfredsson; Nicholas Muzyczka; Ronald J Mandel
Journal:  Mol Ther       Date:  2007-06-12       Impact factor: 11.454

7.  Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice.

Authors:  Hiroyuki Nakai; Sally Fuess; Theresa A Storm; Shin-ichi Muramatsu; Yuko Nara; Mark A Kay
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat.

Authors:  Ronald L Klein; Robert D Dayton; Wen-Lang Lin; Dennis W Dickson
Journal:  Neurobiol Dis       Date:  2005-10       Impact factor: 5.996

9.  Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart.

Authors:  Zhong Wang; Tong Zhu; Chunping Qiao; Liqiao Zhou; Bing Wang; Jian Zhang; Chunlian Chen; Juan Li; Xiao Xiao
Journal:  Nat Biotechnol       Date:  2005-02-27       Impact factor: 54.908

10.  Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats.

Authors:  Jean-Charles Paterna; Joram Feldon; Hansruedi Büeler
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more
  96 in total

Review 1.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

2.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

Review 3.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

4.  Disrupting function of FK506-binding protein 1b/12.6 induces the Ca²+-dysregulation aging phenotype in hippocampal neurons.

Authors:  John C Gant; Kuey-Chu Chen; Christopher M Norris; Inga Kadish; Olivier Thibault; Eric M Blalock; Nada M Porter; Philip W Landfield
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

5.  Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis.

Authors:  Qingli Xiao; So-Chon Gil; Ping Yan; Yan Wang; Sharon Han; Ernie Gonzales; Ronaldo Perez; John R Cirrito; Jin-Moo Lee
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

6.  CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sandra Motas; Virginia Haurigot; Miguel Garcia; Sara Marcó; Albert Ribera; Carles Roca; Xavier Sánchez; Víctor Sánchez; Maria Molas; Joan Bertolin; Luca Maggioni; Xavier León; Jesús Ruberte; Fatima Bosch
Journal:  JCI Insight       Date:  2016-06-16

Review 7.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

8.  Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice.

Authors:  Niki C Carty; Kevin Nash; Daniel Lee; Mary Mercer; Paul E Gottschall; Craig Meyers; Nicholas Muzyczka; Marcia N Gordon; Dave Morgan
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

9.  Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states.

Authors:  Ronald L Klein; Robert D Dayton; Jason B Tatom; Cynthia G Diaczynsky; Michael F Salvatore
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

10.  Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.

Authors:  S K Powell; N Khan; C L Parker; R J Samulski; G Matsushima; S J Gray; T J McCown
Journal:  Gene Ther       Date:  2016-09-15       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.